Church C

Coghlan JG

Condliffe R

Harbaum L

Howard LS

Kiely DG

Law M

Lordan J

Mckie MA

Rothman A

Roussakis AA

Suntharalingam J

Toshner M

Villar SS

Wilkins MR

Wort SJ

\ua9 The Author(s) 2021.Pulmonary arterial hypertension is an unmet clinical need. Imatinib, a tyrosine kinase inhibitor, 200 to 400 mg daily reduces pulmonary artery pressure and increases functional capacity in this patient group, but is generally poorly tolerated at the higher dose. We have designed an open-label, single-arm clinical study to investigate whether there is a tolerated dose of imatinib that can be better targeted to patients who will benefit. The study consists of two parts. Part 1 seeks to identify the best tolerated dose of Imatinib in the range from 100 and up to 400 mg using a Bayesian Continuous Reassessment Method. Part 2 will measure efficacy after 24 weeks treatment with the best tolerated dose using a Simon’s two-stage design. The primary efficacy endpoint is a binary variable. For patients with a baseline pulmonary vascular resistance (PVR) &gt;1000 dynes \ub7 s \ub7 cm−5, success is defined by an absolute reduction in PVR of ≥300 dynes \ub7 s \ub7 cm−5 at 24 weeks. For patients with a baseline PVR ≤1000 dynes \ub7 s \ub7 cm−5, success is a 30% reduction in PVR at 24 weeks. PVR will also be evaluated as a continuous variable by genotype as an exploratory analysis. Evaluating the response to that dose by genotype may inform a prospective biomarker-driven study

Newcastle University E-Prints

Positioning imatinib for pulmonary arterial hypertension: A phase I/II design comprising dose finding and single-arm efficacy

Positioning imatinib for pulmonary arterial hypertension: A phase I/II design comprising dose finding and single-arm efficacy

Abstract

Similar works

Full text

Available Versions

Newcastle University E-Prints